This paper summarizes the current understanding of FTY720, a functional antagonist at S1P1, and discusses about the feasibility of S1P1 as a useful target for treatment of multiple sclerosis (MS), an autoimmune diseases in the central nervous system (CNS). Here, S1PR1 is linked to multiple sclerosis.